Mirvetuximab Soravtansine

An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
02420162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Mirvetuximab soravtansine, an antibody-drug conjugate that binds with high affinity to folate receptor-α to provide tumor… (More)
Is this relevant?
Review
2018
Review
2018
Resistance to platinum-based therapy poses a significant clinical challenge for the management of advanced ovarian cancer, a… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2017
2017
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate receptor α (FRα). In… (More)
Is this relevant?
2017
2017
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an… (More)
Is this relevant?
2017
2017
PURPOSE To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian… (More)
Is this relevant?
Review
2017
Review
2017
Volume 5 • Issue 2 • 1000195 Health Care Current Reviews, an open access journal ISSN:2375-4273 In a recent issue of Neoplasia… (More)
Is this relevant?
2017
2017
In targeting DNA repair pathways of the most genomic instable cancer, poly-(adenosine diphosphate [ADP])-ribose polymerase… (More)
Is this relevant?
2017
2017
Antibody-drug-conjugates (ADCs) are an emerging class of biological therapeutics. Mirvetuximab soravtansine is a novel folate… (More)
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
Review
2017
Review
2017
Antibody–drug conjugates (ADCs) are complex immunoconjugates designed to selectively deliver toxic small molecules preferentially… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
2016
2016
Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?